

1. List of articles in international scientific journals, peer reviewed

1. Agapito-Tenfen SZ, **Okoli AS**, Bernstein MJ, Wikmark OG, Myhr AI. (2018). Revisiting Risk Governance of GM Plants: The Need to Consider New and Emerging Gene-editing Techniques. *Front. Plant Sci.* 9:1874. doi: 10.3389/fpls.2018.01874. eCollection 2018
2. Njambe Priso GD, Lissom A, Ngu LN, Nji NN, Tchadji JC, Tchouangueu TF, Ambada GE, Ngane CSS, Dafeu BL, Djukouo L, Nyebe I, Magagoum S, Ngoh AA, Herve OF, Garcia R, Gutiérrez A, **Okoli AS**, Esimone CO, Njiokou F, Park CG, Waffo AB, Nchinda GW. (2018). Filaria specific antibody response profiling in plasma from anti-retroviral naïve Loa loa microfilaraemic HIV-1 infected people. *BMC Infect Dis.* 18. Doi: 10.1186/s12879-018-3072-2.
3. **Okoli AS**, Okeke MI, Tryland M, Moens U (2018). CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development. *Viruses.* 10. doi: 10.3390/v10010050.
4. Kaare M. Nielsen, Tor GjØen, Nana Asare, BjØrn-Tore Lunestad, Siamak Yazdankhah, BjØrnar Ytrehus, Jacques Godfroid, Anders Jelmert, JØrn Klein, **Arinze Okoli**, Arne Tronsmo,. Antimicrobial resistance in wildlife - potential for dissemination. Opinion of the Panel on Microbial Ecology, Norwegian Scientific Committee for Food and Environment. VKM report 2018:07, ISBN: 978-82-8259-304-5, ISSN: 2535-4019. Norwegian Scientific Committee for Food and Environment (VKM), Oslo, Norway.
5. Okeke MI, **Okoli AS**, Diaz D, Offor C, Oludotun TG, Tryland M, BØhn T, Moens U (2017). Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps? *Viruses.* 9. doi: 10.3390/v9110318.
6. Ngu LN, Nji NN, Ambada G, Ngoh AA, Njambe Priso GD, Tchadji JC, Lissom A, Magagoum SH, Sake CN, Tchouangueu TF, Chukwuma GO, **Okoli AS**, Sagnia B, Chukwuanukwu R, Tebit DM, Esimone CO, Waffo AB, Park CG, Überla K, Nchinda GW. (2017). *Immun Inflamm Dis.* doi: 10.1002/iid3.209
7. **Arinze Okoli** (chair), Nana Asare (VKM staff), Tor GjØen, JØrn Klein, and BjØrnar Ytrehus (2016). Knowledge base for the assessment of environmental risks by the use of genetically modified virus-vectored vaccines for domesticated animals. Scientific Opinion of the Panel on Microbial Ecology of the Norwegian Scientific Committee for Food Safety (VKM). ISBN: 978-82-8259-239-0, Oslo, Norway
8. Skaar, I., Asare, N., Klein, J., **Okoli, A.** and Ruus, A. (2016). «Health and risk evaluation of microorganisms used in bioremediation», Scientific Opinion of the Panel on Microbial Ecology of the Norwegian Scientific Committee for Food Safety (VKM). ISBN: 978-82-8259-232-1, Oslo, Norway.
9. Kunle Okaiyeto, Uchechukwu U. Nwodo, Arinze S. Okoli, Leonard V. Mabinya, Anthony I. Okoh (2016). Studies on a Bioflocculant Production by *Bacillus* sp. AEMREG7. *Polish Journal of Environmental Studies*, 25(1): 236-245.
10. Okaiyeto K, Mabinya LV, Nwodo UU, Okoli, A.S. and Okoh AI (2016). Implications for public health demands alternatives to inorganic and synthetic flocculants: Bioflocculants as important candidates. *MicrobiologyOpen.* doi: 10.1002/mbo3.334.

11. Kunle Okaiyeto, Uchechukwu U. Nwodo, Okoli, A.S., Leonard V. Mabinya and Anthony I. Okoh. (2015). Evaluation of flocculating performance of a thermostable bioflocculant produced by marine *Bacillus* sp. *Env Tech.* 37(14), 1829–1842.
12. Okaiyeto, K., Nwodo, U.U., Mabinya, L.V., [Okoli, A.S.](#) and Okoh, A.I. (2015). [Characterization of a Bioflocculant \(MBF-UFH\) Produced by *Bacillus* sp. AEMREG7](#), *Int. J. Mol. Sci.* 2015, 16, 12986-13003; doi:10.3390/ijms160612986
13. **Okeke M.I., Okoli A.S.,** Eze E.N., Ekwueme G.C., Okosa, E.U and Iroegbu C.U (2015). «*Antibacterial activity of Citrus limonium fruit juice extract*», *Pak J Pharm Sci*, 28(5), 1567-1571. PMID: 26408878
14. Okeke, M.I., Okoli, A.S., Nilssen, O., Moens, U., Tryland, M., Bøhn, T., and Traavik, T. (2014). «Molecular characterization and phylogenetics of Fennoscandian cowpox virus isolates based on the p4c and atip genes». *Virology Journal*. 2014 Jun 27;11 (1):119. doi: 10.1186/1743-422X-11-119.
15. A. C. Krelle, Okoli, A.S., G. L. Mendz (2013). Huh-7 Human Liver Cancer Cells: A Model System to Understand Hepatocellular Carcinoma and Therapy. *Journal of Cancer Therapy*. Pages 606-631. DOI: 10.4236/jct.2013.42078
16. Okoli, A.S., M.J. Raftery and G.L. Mendz. (2012). Comparison of *Helicobacter bilis*-Associated Protein Expression in Huh7 Cells Harbouring HCV Replicon and in Replicon-Cured Cells. *International Journal of Hepatology*. Vol 2012, Article ID 501671, 16 pages. DOI: 10.1155/2012/501671
17. Okoli, A.S., M.J. Raftery and G.L. Mendz. (2012). Effects of Human and Porcine bile on the proteome of *Helicobacter hepaticus*. *Proteome Science*. 10:27
18. Tania E. Farrar, Okoli, A.S., George L. Mendz. (2012). “*Campylobacter* spp. Responses to the Environment and Adaptations to Hosts”. In Hin-chung Wong (ed), *Stress Response of Foodborne Microorganisms*, Nova Science Publishers, Hauppauge, NY, Chapter 8. ISBN: 9781611228106.
19. Okoli, A.S., M.R. Wilkins, M.J. Raftery and G.L. Mendz. (2010). The Response of *H. hepaticus* To Bovine Bile. *J Proteome Res*. 9(3):1374-84.
20. Okoli, A.S., C. Armalle and G.L. Mendz. (2009) The Year in *Helicobacter*: Other *Helicobacter* species. *Helicobacter*. 14 (1): 69-74.
21. Q. V. Tu, Okoli, A.S., Z. Kovach and G. L. Mendz. (2009). Hepatocellular Carcinoma: Prevalence of *Helicobacter* spp. and Molecular Pathogenesis. *Future Microbiol*. 4:1283-13301.
22. Megan Duckworth, Okoli, A.S. and G.L. Mendz. (2009). Novel *Helicobacter pylori* therapeutic targets: the unusual suspects. *Expert Rev. Anti. Infect. Ther.* 7(7): 835-867.
23. Okoli, A.S. (2010). Insight into Host Adaptation of Enterohepatic *Helicobacter* Bacteria: A molecular study of the response of *Helicobacter hepaticus* to bile, and the effect of *Helicobacter*

bilis on human hepatoma cells. PhD Thesis. University of New South Wales, Sydney, Australia. VDM Verlag Dr. Muller Aktiengesellschaft & Co. KG. ISBN: 978-3-639-27414-1

24. Okoli, A.S., T. Wadstrom and G.L. Mendz. (2007). Bioinformatic Study of Bile Responses in Campylobacterales. *FEMS Immunology & Medical Microbiology* 49: 101-103.
25. Okoli, A.S., E.M. Fox, M.J. Raftery and G.L. Mendz. (2007). Effects of *Helicobacter hepaticus* on the proteome of HEP-2 cells. *Antonie van Leeuwenhoek*. 92: 289-300.
26. C.O. Okoli, P. A. Akah, and Okoli, A.S. (2007). Potentials of leaves of *Aspilia africana* (Compositae) in wound care: an experimental evaluation. *BMC Complement & Alternative Medicine*. 7:24. Doi:10.1186/1472-6882-7-24.
27. Okoli, A.S. and C.U. Iroegbu (2005). In Vitro Antibacterial Activity of *Synclisa Scabrida* Whole Root Extracts. *African Journal of Biotechnology* 4: 946-952.
28. Okoli, A.S., and C.U. Iroegbu (2004). Evaluation of Extracts of *Anthocleista Djalensis*, *Nauclea Latifolia* and *Uvaria Afzalii* for Activity against Bacterial Isolates from cases of Non-Gonococcal Urethritis. *Journal of Ethnopharmacology*. 92: 135-144.
29. Okoli, A.S., M.I. Okeke, C.U. Iroegbu and P.U. Ebo (2002). Antibacterial Activity of *Harungana madagascariensis* Leaf Extracts. *Phytotherapy Research* 15: 1-6.
30. M.I. Okeke, C.U. Iroegbu, E.N. Eze, Okoli, A.S. (2001). Evaluation of Extracts of the Root of *Landolphia owerrience* for Antibacterial Activity. *Journal of Ethnopharmacology*. 78: 119-127.
31. M.I. Okeke, C.U. Iroegbu, C.O. Jideofor, Okoli, A.S., and C.O. Esimone (2000). Antimicrobial Activity of Ethanol Extracts of two Indigenous Nigerian Spices. *Journal of Herbs, Spices and Medicinal Plants* 8: 39-46.

2. Other international publications with peer review (conference papers –refereed and published)

1. Kunle Okaiyeto, Uchechukwu U. Nwodo, **Arinze S. Okoli**, Leonard V. Mabinya and Anthony I. Okoh (2015). Culture conditions optimization and characterization of a bioflocculant produced by *Bacillus* sp. isolated from Algoa Bay, South Africa. *J Microbiol Biochem Technol*, 5:4.
2. **A.S. Okoli** and G.L. Mendz. (2007). Effects of Bovine, porcine and Human Bile on the Protein Expression of *Helicobacter hepaticus*. 14th International Workshop on *Campylobacter*, *Helicobacter* and Related Organisms. Rotterdam, The Netherlands, September 2-5. Abstract No.; P137. *Zoonoses and Public Health*. **54**: 57. **ESCMID Grant**.
3. **A.S. Okoli**, M.R. Wilkins, M.J. Raftery and G.L. Mendz. (2007). Proteomic Investigation of Effects of *Helicobacter bilis* on the Human Hepatoma Huh7 Cell Line. 14th International Workshop on *Campylobacter*, *Helicobacter* and Related Organisms. Rotterdam, The Netherlands, September 2-5. Abstract No.; P252. *Zoonoses and Public Health*. **54**: 88. **[Poster presentation]. ESCMID Grant**

- 4 Z. Kovach, Q.V. Tu, G. Chang, **A.S. Okoli**, W.G. Miller and G.L. Mendz. (2007). Changes in the Expression of Virulence-Related Genes in Response to Ox Bile of six Species of Campylobacterales. 14th International Workshop on *Campylobacter*, *Helicobacter* and Related Organisms. Rotterdam, The Netherlands, September 2-5. Abstract No.; P289. *Zoonoses and Public Health*. **54**: 98.

3. International publications without peer review (Technical Reports)

1. **Okoli, A.S.** (2016). Ensuring synthetic biology safety: lessons from the era of virus-based GM vaccines and gene therapy medicinal products. **In:** Wikmark, O.-G., Brautaset, T., Agapito-Tenfen, S.Z., **Okoli, A.S.**, Myhr, A.I., Binimelis, R. and Ching, L.L. «Synthetic biology – biosafety and contribution to addressing societal challenges», Biosafety Report 02/16, GenØk-Centre for Biosafety, Tromsø, Norway.
2. **Okoli, A.S.** and Okeke, M.I. (2015). GM vaccines, Gene Therapy and Medicinal Products containing or consisting of GMOs. In: Lise Nordgård, Thomas Bøhn, Frøydis Gillund, Idun Merete Grønsberg, Marianne Iversen, Anne Ingeborg Myhr, Malachy Ifeanyi Okeke, Arinze Stanley Okoli, Hermoine Venter, Odd-Gunnar Wikmark. Uncertainties and knowledge gaps related to environmental risk assessment of GMOs.

4. Attendance at conferences/workshops in the last 7years, 2012 – 2018

1. **Okoli, A.S.**, Jennifer A.L. Nunn, Anne Myhr, Idun Grønsberg, Najam Zubai, Nick Niyonzima (2019). CRISPR/Cas9 as a potential safe and sustainable solution to the problem of infectious salmon anemia disease in Norway. DigitalLife Conference September 5-6, 2019, Tromsø, Norway. **(Poster presentation)**
2. **Okoli, A.S.** (2018). Gene-Editing, Synthetic Biology & Gene Drive: need to revisit RA protection goals and regulatory landscape. Fourth National Biosafety Conference. 12-13 September, 2018. Ambrose Alli University, Benin, Edo State, Nigeria. **(Invited speaker and resource person)**
3. **Okoli, A.S.** (2016). *Judging the risk of synthetic biology: what can the ERA of GM vaccines and gene therapy medicinal products teach us?* **In:** Experiences from a GenØks Capacity building program: Synthetic biology, uncertainties and contribution to solving societal challenges. A side event at the meeting of the Conference of the Parties to the Convention on Biological Diversity and meeting of the Parties to the Cartagena Protocol on Biosafety (COP-MOP). December 04-17, 2016, Cancun, Mexico. **(Invited speaker and Faculty member)**
4. **Okoli AS** (2016). Application of Proteomics in the study of Microbial Physiology: *taking advantage of changes in the microbe's normal functions under stress conditions*. 5th Conference on Microbial Physiology and Genomics. September 29-30, 2016. London, United Kingdom. **(Invited speaker)**
5. Stenger KS, Forbes, E., Wikmark, O-G, **Okoli AS** (2016). Identification of the response pathways of *E. coli* and *E. faecalis* to Glyphosate and AMPA. 5th Conference on Microbial Physiology and Genomics. September 29-30, 2016. London, United Kingdom.
6. Okaiyeto K, **Okoli AS**, Nwodo UU, Mabinya LV, Okoh AI (2016) Assessment of flocculating activity of a bioflocculant by a *Bacillus* sp. isolated from marine environment. A paper presented at the University of Fort Hare Centenary Conference held on the 3rd-6th July at the University of Fort Hare Alice campus, South Africa.
7. **Okoli, A.S.** (2016). Ensuring synthetic biology safety: what can the ERA of GM vaccine and gene therapy product teach us? Synthetic biology workshop. May 09-16, 2016. Bogor, Agricultural University, Indonesia **(Invited speaker and Faculty member)**

8. Kunle Okaiyeto, Uchechukwu U. Nwodo, Leonard V. Mabinya, **Arinze S. Okoli** and Anthony I. Okoh (2015). Characterization and flocculating efficiency of a bioflocculant (MBF-UFH) produced by *Bacillus* sp. an alternatives to hazardous chemical flocculants used in water treatment. VI International Conference on Environmental, Industrial and Applied Microbiology – BioMicroWorld 2015 (Barcelona-Spain, 28-30 October 2015).
9. Kunle Okaiyeto, Uchechukwu U. Nwodo, Leonard V. Mabinya, **Arinze S. Okoli** and Anthony I. Okoh (2015). Investigation of flocculating efficiency and characterization of biopolymer (MBF-UFH) produced by *Bacillus* sp. AEMREG7. 4th YWP-ZA Biennial and 1st African YWP Conference, 16-18 November, 2015, Pretoria, South Africa.
10. Okoli, A.S. (2015). Ensuring Synthetic Biology Safety: what can the ERA of Gene Therapy Drug Products and Transgenic Vaccines teach us? Synthetic Biology Workshop, 20-26th September 2015, North-West University, Potchefstroom, South Africa (**Invited speaker and Faculty member**)
11. Nwodo UU, Okoh AI and **Okoli AS** (2014). Understanding the mechanisms underlying bacterial bio-flocculant production. 2nd International Congress on Bacteriology and Infectious Diseases” during November 17-19, 2014 Chicago, USA.
12. **A.S. Okoli**, M. I. Okeke, C. Tummler, U. Moens, Ø. Nilssen, M. Tryland, J. A. Bruun, T. Bøhn and T. Traavik. (2013). Host cell response to a recombinant modified vaccinia virus Ankara-based vaccine. 11th ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC, USA. February 25th-27th [Highlighted Oral Presentation]; [**ASM & Battelle Post-Doc Grant Award Recipient**].
13. **A.S. Okoli**, M.I. Okeke, U. Moens, Ø. Nilssen, M. Tryland, J.A. Bruun, T. Bøhn and T. Traavik. (2012). Delineating the infectome of modified virus Ankara using quantitative proteomics. 6th European Summer School. Kloster Neustift (Brixen/Bressanone), South Tirol, Italy. August 19th -25th [Poster Presentation]; [**Norwegian Proteomic Grant Award Recipient**].
14. **A.S. Okoli**, M.I. Okeke, U. Moens, Ø. Nilssen, M. Tryland, J.A. Bruun, T. Bøhn and T. Traavik. (2012). SILAC-based quantitative proteomics provides insight into the infectome of modified virus Ankara (MVA) and its transgenic variant (hanpMVA) in BHK-21 infected cells. 7th Norwegian National Proteomic Meeting. Tromsø, Norway. March 19th-20th [Oral Presentaion].